Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Breast Cancer

  Free Subscription

Articles published in J Nucl Med

Retrieve available abstracts of 40 articles:
HTML format

Single Articles

    May 2021
  1. JACENE HA, Liu M, Cheng SC, Abbott A, et al
    Imaging Androgen Receptors in Breast Cancer with (18)F-fluoro-5alpha-dihydrotestosterone-PET: A Pilot Study.
    J Nucl Med. 2021 May 28. pii: jnumed.121.262068. doi: 10.2967/jnumed.121.262068.
    PubMed     Abstract available

  2. MORAWITZ J, Bruckmann NM, Dietzel F, Ullrich T, et al
    Determining the axillary nodal status with four current imaging modalities including (18)F-FDG PET/MRI in newly diagnosed breast cancer: A comparative study using histopathology as reference standard.
    J Nucl Med. 2021 May 20. pii: jnumed.121.262009. doi: 10.2967/jnumed.121.262009.
    PubMed     Abstract available

  3. BOERS J, Loudini N, Brunsch CL, Koza SA, et al
    Value of (18)F-FES-PET to solve clinical dilemmas in breast cancer patients: a retrospective study.
    J Nucl Med. 2021 May 14. pii: jnumed.120.256826. doi: 10.2967/jnumed.120.256826.
    PubMed     Abstract available

    December 2020
  4. D'HUYVETTER M, De Vos J, Caveliers V, Vaneycken I, et al
    Phase I trial of (131)I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients.
    J Nucl Med. 2020 Dec 4. pii: jnumed.120.255679. doi: 10.2967/jnumed.120.255679.
    PubMed     Abstract available

  5. VISWANATH V, Zhou R, Lee H, Li S, et al
    Kinetic Modeling of (18)F-(2S,4R)4-Fluoroglutamine in Mouse Models of Breast Cancer to Estimate Glutamine Pool Size as an Indicator of Tumor Glutamine Metabolism.
    J Nucl Med. 2020 Dec 4. pii: jnumed.120.250977. doi: 10.2967/jnumed.120.250977.
    PubMed     Abstract available

    October 2020
  6. VIDAL-SICART S, Rioja ME, Prieto A, Goni E, et al
    Sentinel Lymph Node Biopsy in breast cancer with (99m)Tc-Tilmanocept: A novel tracer in the real life. A multicenter study.
    J Nucl Med. 2020 Oct 9. pii: jnumed.120.252064. doi: 10.2967/jnumed.120.252064.
    PubMed     Abstract available

    August 2020
  7. KUMAR M, Salem K, Jeffery JJ, Yan Y, et al
    Longitudinal molecular imaging of progesterone receptor reveals early differential response to endocrine therapy in breast cancer with an activating ESR1 mutation.
    J Nucl Med. 2020 Aug 28. pii: jnumed.120.249508. doi: 10.2967/jnumed.120.249508.
    PubMed     Abstract available

  8. BRAGINA O, von Witting E, Garousi J, Zelchan R, et al
    Phase I study of (99m)Tc-ADAPT6, a scaffold protein-based probe for visualization of HER2 expression in breast cancer.
    J Nucl Med. 2020 Aug 17. pii: jnumed.120.248799. doi: 10.2967/jnumed.120.248799.
    PubMed     Abstract available

  9. VAN ES SC, Velleman T, Elias SG, Bensch F, et al
    Assessment of Bone Lesions with (18)F-FDG-PET Compared to (99m)Technetium Bone Scintigraphy Leads to Clinically Relevant Differences in Metastatic Breast Cancer Management.
    J Nucl Med. 2020 Aug 17. pii: jnumed.120.244640. doi: 10.2967/jnumed.120.244640.
    PubMed     Abstract available

    July 2020
  10. ULANER GA, Jhaveri K, Chardarlapaty S, Hatzoglou V, et al
    Head-to-head evaluation of (18)F-FES and (18)F-FDG PET/CT in metastatic invasive lobular breast cancer.
    J Nucl Med. 2020 Jul 17. pii: jnumed.120.247882. doi: 10.2967/jnumed.120.247882.
    PubMed     Abstract available

    June 2020
  11. PETERSON LM, Kurland BF, Yan F, Novakova-Jiresova A, et al
    (18)F-Fluoroestradiol ((18)F-FES)-PET imaging in a Phase II trial of vorinostat to restore endocrine sensitivity in ER+/HER2- metastatic breast cancer.
    J Nucl Med. 2020 Jun 26. pii: jnumed.120.244459. doi: 10.2967/jnumed.120.244459.
    PubMed     Abstract available

  12. BARATTO L, Duan H, Macke H, Iagaru A, et al
    Imaging the Distribution of Gastrin-Releasing Peptide Receptors in Cancer.
    J Nucl Med. 2020;61:792-798.
    PubMed     Abstract available

    March 2020
  13. ROUSSEAU C, Goldenberg DM, Colombie M, Sebille JC, et al
    Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in HER2-negative Breast Cancer.
    J Nucl Med. 2020 Mar 13. pii: jnumed.119.236000. doi: 10.2967/jnumed.119.236000.
    PubMed     Abstract available

    January 2020
  14. LAFFON E, Marthan R
    SUVmax-V for assessing treatment response in FDG-PET Imaging of Patient-Derived Tumor Xenografts involving Triple-Negative Breast Cancer.
    J Nucl Med. 2020 Jan 10. pii: jnumed.120.241778. doi: 10.2967/jnumed.120.241778.

    December 2019
  15. HERNANDEZ R, Grudzinski JJ, Aluicio-Sarduy E, Massey CF, et al
    (177)Lu-NM600 targeted radionuclide therapy extends survival in syngeneic murine models of triple-negative breast cancer.
    J Nucl Med. 2019 Dec 20. pii: jnumed.119.236265. doi: 10.2967/jnumed.119.236265.
    PubMed     Abstract available

  16. MCDONALD ES, Doot RK, Young AJ, Schubert EK, et al
    Breast Cancer (18)F-ISO-1 Uptake as a Marker of Proliferation Status.
    J Nucl Med. 2019 Dec 13. pii: jnumed.119.232363. doi: 10.2967/jnumed.119.232363.
    PubMed     Abstract available

    November 2019
  17. BIEGON A, Shroyer KR, Franceschi D, Dhawan J, et al
    Initial studies with [(11)C]vorozole positron emission tomography detect over-expression of intra-tumoral aromatase in breast cancer.
    J Nucl Med. 2019 Nov 22. pii: jnumed.119.231589. doi: 10.2967/jnumed.119.231589.
    PubMed     Abstract available

  18. SAVAIKAR MA, Whitehead T, Roy S, Strong L, et al
    SUV25 and microPERCIST: Precision Imaging of Response to Therapy in Co-Clinical FDG-PET Imaging of Triple Negative Breast Cancer (TNBC) Patient-Derived Tumor Xenografts (PDX).
    J Nucl Med. 2019 Nov 22. pii: jnumed.119.234286. doi: 10.2967/jnumed.119.234286.
    PubMed     Abstract available

  19. KUMAR M, Salem K, Tevaarwerk AJ, Strigel RM, et al
    Recent Advances in Imaging Steroid Hormone Receptors in Breast Cancer.
    J Nucl Med. 2019 Nov 15. pii: jnumed.119.228858. doi: 10.2967/jnumed.119.228858.
    PubMed     Abstract available

    September 2019
  20. LEUNG CN, Canter BS, Rajon D, Back TA, et al
    Dose-Dependent Growth Delay of Breast Cancer Xenografts in the Bone Marrow of Mice Treated with Radium-223: The Role of Bystander Effects and their Potential for Therapy.
    J Nucl Med. 2019 Sep 13. pii: jnumed.119.227835. doi: 10.2967/jnumed.119.227835.
    PubMed     Abstract available

  21. RAMOS N, Baquero J, Gironda Z, Zaim-Wadghiri Y, et al
    Non invasive PET imaging of CDK4/6 activation in Breast Cancer.
    J Nucl Med. 2019 Sep 3. pii: jnumed.119.232603. doi: 10.2967/jnumed.119.232603.
    PubMed     Abstract available

    June 2019
  22. LEITHNER D, Helbich TH, Bernard-Davila B, Marino MA, et al
    Multiparametric (18)F-FDG PET-MRI of the breast: are there differences in imaging biomarkers of contralateral healthy tissue between patients with and without breast cancer?
    J Nucl Med. 2019 Jun 28. pii: jnumed.119.230003. doi: 10.2967/jnumed.119.230003.
    PubMed     Abstract available

    March 2019
  23. AZAD G, Siddique M, Taylor B, Green A, et al
    Reply to: Relevance of measurement uncertainty for quantitative response assessment of breast cancer bone metastases with (18)F-fluoride.
    J Nucl Med. 2019 Mar 8. pii: jnumed.119.226555. doi: 10.2967/jnumed.119.226555.

  24. KUMAR M, Salem K, Michel CJ, Jeffery JJ, et al
    (18)F-Fluoroestradiol Positron Emission Tomography Imaging of Activating Estrogen Receptor Alpha Mutations in Breast Cancer.
    J Nucl Med. 2019 Mar 8. pii: jnumed.118.224667. doi: 10.2967/jnumed.118.224667.
    PubMed     Abstract available

    February 2019
  25. LAFFON E, Marthan R
    Relevance of measurement uncertainty for quantitative response assessment of breast cancer bone metastases with (18)F-fluoride.
    J Nucl Med. 2019 Feb 7. pii: jnumed.119.226092. doi: 10.2967/jnumed.119.226092.

    January 2019
  26. DOOT RK
    Practical methods for estimating metabolic flux (Ki) to assess response to therapy via static PET scans.
    J Nucl Med. 2019 Jan 25. pii: jnumed.118.220913. doi: 10.2967/jnumed.118.220913.

  27. MORTIMER JE, Shively JE
    Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers and a Note about NOTA.
    J Nucl Med. 2019;60:23-25.

    September 2018
  28. ULANER GA, Juarez J, Riedl C, Goldman D, et al
    (18)F-FDG PET/CT for Systemic Staging of Newly Diagnosed Breast Cancer in Men.
    J Nucl Med. 2018 Sep 20. pii: jnumed.118.217836. doi: 10.2967/jnumed.118.217836.
    PubMed     Abstract available

    July 2018
  29. AZAD G, Siddique MM, Taylor B, Green A, et al
    Does measurement of (18)F-fluoride metabolic flux improve response assessment of breast cancer bone metastases compared with standardised uptake values in (18)F-fluoride PET/CT?
    J Nucl Med. 2018 Jul 24. pii: jnumed.118.208710. doi: 10.2967/jnumed.118.208710.
    PubMed     Abstract available

  30. SALEM K, Kumar M, Yan Y, Jeffery JJ, et al
    Sensitivity and Isoform Specificity of (18)F-Fluorofuranylnorprogesterone for Measuring Progesterone Receptor Protein Response to Estradiol Challenge in Breast Cancer.
    J Nucl Med. 2018 Jul 20. pii: jnumed.118.211516. doi: 10.2967/jnumed.118.211516.
    PubMed     Abstract available

    June 2018
  31. KURLAND BF, Oesterreich S
    Heterogeneity in metastatic breast cancer (18)F-fluoroestradiol uptake - clinically actionable, biologically illuminating?
    J Nucl Med. 2018 Jun 14. pii: jnumed.118.214304. doi: 10.2967/jnumed.118.214304.

  32. SAH BR, Ghafoor S, Burger IA, Ter Voert EEGW, et al
    Feasibility of (18)F-FDG Dose Reductions in Breast Cancer PET/MRI.
    J Nucl Med. 2018 Jun 7. pii: jnumed.118.209007. doi: 10.2967/jnumed.118.209007.
    PubMed     Abstract available

    May 2018
  33. PETERSON LM, O'Sullivan J, Wu QV, Novakova-Jiresova A, et al
    Prospective study of serial (18)F-FDG PET and (18)F-fluoride ((18)F-NaF) PET to predict time to skeletal related events, time-to-progression, and survival in patients with bone-dominant metastatic breast cancer.
    J Nucl Med. 2018 May 10. pii: jnumed.118.211102. doi: 10.2967/jnumed.118.211102.
    PubMed     Abstract available

    April 2018
  34. WU J, Wang S, Zhang X, Teng Z, et al
    (18)F-Alfatide II PET/CT for Identification of Breast Cancer: A Preliminary Clinical Study.
    J Nucl Med. 2018 Apr 26. pii: jnumed.118.208637. doi: 10.2967/jnumed.118.208637.
    PubMed     Abstract available

    Now is the time to use FDG-PET/CT to optimize neoadjuvant treatment in triple negative breast cancer!
    J Nucl Med. 2018 Apr 19. pii: jnumed.118.210922. doi: 10.2967/jnumed.118.210922.

    March 2018
  36. NIENHUIS HH, van Kruchten M, Elias SG, Glaudemans AWJM, et al
    ((18))F-fluoroestradiol Tumor Uptake is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients.
    J Nucl Med. 2018 Mar 30. pii: jnumed.117.198846. doi: 10.2967/jnumed.117.198846.
    PubMed     Abstract available

  37. MONTEMAGNO C, Bacot S, Ahmadi M, Kerfelec B, et al
    Preclinical evaluation of novel mesothelin-specific ligands for SPECT imaging of Triple Negative Breast Cancer.
    J Nucl Med. 2018 Mar 23. pii: jnumed.117.203489. doi: 10.2967/jnumed.117.203489.
    PubMed     Abstract available

    February 2018
  38. HUMBERT O, Lasserre M, Bertaut A, Fumoleau P, et al
    Pattern of breast cancer blood flow and metabolism, assessed using dual-acquisition (18)FDG PET: correlation with tumor phenotypic features and pathological response to neoadjuvant chemotherapy.
    J Nucl Med. 2018 Feb 9. pii: jnumed.117.203075. doi: 10.2967/jnumed.117.203075.
    PubMed     Abstract available

    November 2017
  39. ULANER GA, Lyashchenko SK, Riedl C, Ruan S, et al
    First-in-human HER2-targeted imaging using 89Zr-pertuzumab PET/CT: Dosimetry and clinical application in patients with breast cancer.
    J Nucl Med. 2017 Nov 16. pii: jnumed.117.202010. doi: 10.2967/jnumed.117.202010.
    PubMed     Abstract available

    September 2017
  40. VENEMA CM, Mammatas LH, Schroder CP, van Kruchten M, et al
    Androgen and estrogen receptor imaging in metastatic breast cancer patients as a surrogate for tissue biopsies.
    J Nucl Med. 2017 Sep 14. pii: jnumed.117.193649. doi: 10.2967/jnumed.117.193649.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.